Inhibitory potency of Valsartan/Sacubitril drug combination: molecular docking simulations

被引:0
|
作者
Jovanovic, Jelena Dorovic [1 ,2 ]
Markovic, Zoran [2 ]
Kokanovic, Mihajlo [1 ]
Filipovic, Nenad [3 ]
Stanojevic, Ma Rijana [4 ]
机构
[1] Bioengn Res & Dev Ctr BioIRC, Kragujevac, Serbia
[2] Univ Kragujevac, Inst Informat Technol, Dept Sci, Kragujevac 34000, Serbia
[3] Univ Kragujevac, Fac Engn, Bioengn Res & Dev Ctr, Kragujevac, Serbia
[4] Univ Kragujevac, Fac Med Sci, Pirkov Dept Biochem, Kragujevac 34000, Serbia
基金
欧盟地平线“2020”;
关键词
Entresto; molecular docking simulations; Neprilysin; Angiotensin II receptor;
D O I
10.1109/BIBE52308.2021.9635185
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Heart failure (HF) is a condition that affects mostly older populations. It can be treated with different medications, and one of them is Entresto. This is a medication which is consisting of two drugs, sacubitril (SAC) and valsartan (VAL). Here, in this study, are performed molecular docking simulations in order to examine the inhibitory potency of SAC and VAL towards neprilysin (NEP) and angiotensin II receptor (AT2), respectively. The achieved thermodynamic parameters shows that SAC and VAL can bind to targeted protein, and inhibit NEP and AT2. The best binding sites are determined. Also, the amino acids responsible for binding are identified.
引用
收藏
页数:4
相关论文
共 50 条
  • [31] Study of the possible effect of sacubitril/valsartan combination versus valsartan on the cognitive function in Alzheimer's disease model in rats
    Hussein, Abdallah Salah El-din
    Abou-El Nour, Rahma Kamal El-Din
    Khorshid, Omayma A.
    Osman, Afaf S.
    INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2023, 37
  • [32] Serious adverse drug reactions with sacubitril/valsartan Entresto®: a French pharmacovigilance survey
    Florence Moulis
    Vanessa Rousseau
    Leila Chebane
    Amandine Gouverneur
    Louise Gaboriau
    Jean-Luc Faillie
    Geneviève Durrieu
    François Montastruc
    Jean-Louis Montastruc
    European Journal of Clinical Pharmacology, 2018, 74 : 983 - 984
  • [33] Exploring inhibitory components of Hedyotis diffusa on androgen receptor through molecular docking and molecular dynamics simulations
    Xiang, Jingjing
    Li, Zefei
    Liu, Qi
    MEDICINE, 2023, 102 (52) : E36637
  • [34] Resolution of Hypoglycemia Following Cessation of Sacubitril-Valsartan Combination Therapy in a Nondiabetic Patient
    Morgan, Georgia
    Chowdhury, Sharmistha Roy
    CJC OPEN, 2023, 5 (03) : 396 - 399
  • [35] Sacubitril/valsartan combination enhanced cardiac glycophagy and prevented the progression of murine diabetic cardiomyopathy
    Elshenawy, Dina Salem Abdelaziz
    Ramadan, Nehal Mohammed
    Abdo, Vivian Boshra
    Ashour, Rehab Hamdy
    BIOMEDICINE & PHARMACOTHERAPY, 2022, 153
  • [36] Response to: Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan)
    Petramala, Luigi
    Letizia, Claudio
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2020, 6 (04) : 252 - 252
  • [37] Studies on the Molecular Mechanism between HDAC8 and Inhibitory in Different Bioactivities by Molecular Docking and MD Simulations
    梁振
    严文利
    李红梅
    李颖
    张荣
    ChineseJournalofStructuralChemistry, 2021, 40 (10) : 1298 - 1308
  • [38] SACUBITRIL/VALSARTAN PROTEOMIC BIOMARKERS FOR HEART FAILURE WITH PRESERVED EJECTION FRACTION: MOLECULAR INSIGHTS ASSOCIATED WITH SEX DIFFERENCES IN DRUG RESPONSE
    Thanh Thanh Nguyen
    Wang, Min
    Liu, Duan
    Iyer, Seethalakshmi
    Acker, Nancy
    Bonilla, Hilda Mariana Gonzalez
    Murthy, Vishakantha
    Shrivastava, Sanskriti
    Desai, Viral
    Burnett, John C., Jr.
    Redfield, Margaret M.
    Weinshilboum, Richard
    Pereira, Naveen L.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (09) : 297 - 297
  • [39] Studies on the Molecular Mechanism between HDAC8 and Inhibitory in Different Bioactivities by Molecular Docking and MD Simulations
    Zhen, Liang
    Wen-Li, Yan
    Hong-Mei, Li
    Ying, Li
    Rong, Zhang
    CHINESE JOURNAL OF STRUCTURAL CHEMISTRY, 2021, 40 (10) : 1298 - 1308
  • [40] Can sacubitril/valsartan become the promising drug to delay the progression of chronic kidney disease?
    Yang CHEN
    Lu-Ying GUO
    Ling-Fei ZHAO
    Yan-Hong MA
    Xue-Ling ZHU
    Ying XU
    Jiang-Hua CHEN
    Journal of Geriatric Cardiology, 2020, 17 (12) : 782 - 786